Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/29/2005WO2005089731A2 Use of renin inhibitors in therapy
09/29/2005WO2005089730A2 Dna pkinase inhibitors for treating cancer and diabetes
09/29/2005WO2005089729A2 Galenic formulations of organic compounds
09/29/2005WO2005089728A2 Means for transdermal administration of nicotine
09/29/2005WO2005089723A1 Drug delivery system based on polyethylene vinylacetate copolymers
09/29/2005WO2005089721A1 In process conversion method for preparing tannate tablet, capsule or other solid dosage forms
09/29/2005WO2005089720A1 Valsartan tablets and the process for the preparation thereof
09/29/2005WO2005089717A1 Pharmaceutical formulations for dry powder inhalers comprising a low-dosage strength active ingredient
09/29/2005WO2005089716A1 Preparation with elevated content
09/29/2005WO2005089715A1 Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose
09/29/2005WO2005089714A1 Emulsion stabilizer
09/29/2005WO2005089711A2 Pharmaceutical formulation containing unmilled flutamide
09/29/2005WO2005089707A1 Peeling cosmetic method using a 8-hexadecene-1,16-dicarboxylic acid
09/29/2005WO2005089639A2 Method for vascular dysregulation
09/29/2005WO2005089567A1 Compositions and methods for reducing or preventing obesity
09/29/2005WO2005089566A1 Pet food compositions containing an added boron source
09/29/2005WO2005089522A2 Spermicidal and virucidal properties of various forms of sophorolipids
09/29/2005WO2005089515A2 Methods for the treatment of synucleinopathies
09/29/2005WO2005089503A2 Cd4-igg2 formulations
09/29/2005WO2005089502A2 Methods for the treatment of synucleinopathies
09/29/2005WO2005089496A2 Methods for the treatment of synucleinopathies
09/29/2005WO2005089486A2 Methods for treating alcoholism
09/29/2005WO2005089449A2 Methods for treating alcoholism
09/29/2005WO2005089448A2 Administration of cisplatin by inhalation
09/29/2005WO2005089443A2 Combinatorial methods and compositions for treatment of melanoma
09/29/2005WO2005089441A2 Methods for increasing neurotransmitter levels using hydroxycitric acid
09/29/2005WO2005089372A2 Therapeutic synergy of anti-cancer compounds
09/29/2005WO2005089366A2 Method of treatment of myocardial infarction
09/29/2005WO2005089365A2 Treatment and prevention of abnormal cellular proliferation
09/29/2005WO2005089294A2 Synthesis of indenoisoquinoliniums and methods of use
09/29/2005WO2005089256A2 Antiangiogenic agents
09/29/2005WO2005089224A2 iRNA AGENTS TARGETING VEGF
09/29/2005WO2005089118A2 Novel bicyclic compounds as modulators of androgen receptor function and method
09/29/2005WO2005089106A2 Degradable nanoparticles
09/29/2005WO2005089100A2 Decontamination formulations for disinfection and sterilization
09/29/2005WO2005089066A2 Pharmaceutical compositions, methods of formulation thereof and methods of use thereof
09/29/2005WO2005074513A3 N-benzyl-3,4-dihyroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integrase inhibitors
09/29/2005WO2005074460A3 Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
09/29/2005WO2005073224A3 Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
09/29/2005WO2005070940A3 Rifamycin derivatives effective against drug-resistant microbes
09/29/2005WO2005070042A3 Novel chemical compounds
09/29/2005WO2005067900A3 Azabenzofuran substituted thioureas as inhibitors of viral replication
09/29/2005WO2005067489A3 Type ii diabetes
09/29/2005WO2005065669A8 Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
09/29/2005WO2005065183A3 Mitotic kinesin inhibitors
09/29/2005WO2005063807A3 Treatment of coronary or peripheral ischemia
09/29/2005WO2005062991A3 Ten and 20-di-esterification derivatives of camptothecins and methods to treat cancers
09/29/2005WO2005060947A3 Agonist and antagonist ligands of the nociceptin receptor
09/29/2005WO2005054440A3 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan
09/29/2005WO2005054183A3 Quinolinone based protein kinase inhibitors
09/29/2005WO2005051917A9 Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions
09/29/2005WO2005051350B1 Water dispersible tablet
09/29/2005WO2005049142A3 Graduated estrogen contraceptive
09/29/2005WO2005049090A3 Olanzapine containing transdermal drug delivery compositions
09/29/2005WO2005046688A3 Methods of use of thrombin receptor antagonists
09/29/2005WO2005042697A3 Compounds, compositions and methods
09/29/2005WO2005041925A3 Compositions and dosage forms for enhanced absorption
09/29/2005WO2005040758A3 Use of pirfenidone in therapeutic regimens
09/29/2005WO2005039642A9 Dna delivery with gemini cationic surfactants
09/29/2005WO2005039578A3 Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
09/29/2005WO2005039483A3 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
09/29/2005WO2005025507A3 Dihydropyridine compounds for treating or preventing metabolic disorders
09/29/2005WO2005023192A3 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
09/29/2005WO2005018567A3 Compounds and compositions for the treatment of diabetes and diabetes-related disorders
09/29/2005WO2005018556A3 Hydroxylamine substituted imidazo-containing compounds
09/29/2005WO2005009398A3 Tetracyclic benzamide derivatives and methods of use thereof
09/29/2005WO2005009382A3 Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
09/29/2005WO2005009340A3 Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
09/29/2005WO2005009334A3 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof
09/29/2005WO2005007107A3 Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
09/29/2005WO2005000244A3 Methods and compositions for treating rheumatoid arthritis
09/29/2005WO2004110346A3 Sustained release of antiinfectives
09/29/2005WO2004106299A8 Substituted pyrrole derivatives and their use as hmg-co inhibitors
09/29/2005WO2004094418A8 Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
09/29/2005WO2004089943A8 Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues
09/29/2005WO2004084843A3 Inhibitors of cathepsin s
09/29/2005WO2004076632A3 Methods of screening for trpm5 modulators
09/29/2005WO2004070008A8 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
09/29/2005WO2004069196A3 Novel compounds
09/29/2005WO2004041758A8 New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonistics
09/29/2005WO2004022152A3 Radiotherapy method using x-rays
09/29/2005WO2004012662A3 Improved treatment of cancer with glutamine
09/29/2005WO2003074057A8 Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident
09/29/2005US20050216960 Using tumor necrosis factor related apoptosis inducing ligand receptor (TRAIL-R) to identify modulators of dendritic cell immune response
09/29/2005US20050216427 Multiparameter method of screening for atherosclerosis-related coronary heart disease or stroke
09/29/2005US20050215795 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
09/29/2005US20050215793 dissolving 3-pyridyl-1-hydroxyethyliden-1,1-biphosphonic acid ( risedronic acid) in an aqueous solvent containing water or water and butanol/tert-/, adding a sodium base (NaOH, sodium methoxide, NaHCO3, Na2CO3, sodium acetate), freeze drying the mixture to form risedronate sodium in amorphous powder form
09/29/2005US20050215786 Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,,2,4-triazol-3-one
09/29/2005US20050215784 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
09/29/2005US20050215766 Allergen from mugwort pollen
09/29/2005US20050215748 Surgical adhesive formulations and methods of preparation
09/29/2005US20050215722 Drug delivery compositions and medical devices containing block copolymer
09/29/2005US20050215649 Conjugated alphatic dialdehyde disinfecting and sterilizing compositions and methods of using the same
09/29/2005US20050215648 Oxymethylidene-substituted, e.g., 2-(1-methoxy-ethylidene)-cyclopent-4-ene-1,3-diones; inhibit fluconazole-resistant C. albicans strains; may be used for the treatment of life-threatening candidiasis associated with immunocompromised patients.
09/29/2005US20050215647 N-methyl-3-hydroxy-4,4-dimethyl-2-(2'naphthyl)pentylamine; potent, wide-spectrum antidepressant and treating anxiety disorders
09/29/2005US20050215646 aryl nitrones such as alpha-(4-methoxymethoxy-3,5-di-tert-butyl-phenyl)-N-tert-butylnitrone; in dosage forms
09/29/2005US20050215645 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction
09/29/2005US20050215644 Methods for increasing neurotransmitter levels using hydroxycitric acid
09/29/2005US20050215643 A fast-release diclofenac dosage or its alkali salt in the form of a packet of powder for dissolving or suspending in water, a bilayered tablet that has a fast and a slow release layer, or a liquid drop solution; improving the taste/reducing side effects by the addition of an alkali bicarbonate; times
09/29/2005US20050215642 Aromatic guanidine compound; antitumor agents; anticancer agents; for the treatment of breast cancer
1 ... 4522 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 ... 7860